Author/Authors :
Özsarı, S Şanlıurfa Siverek Devlet Hastanesi - Göğüs Hastalıkları Kliniği, Türkiye , Çok, G Ege Üniversitesi - Tıp Fakültesi,Göğüs Hastalıkları Anabilim Dalı, Türkiye
Title Of Article :
Effectiveness of irinotecan as second-line chemotherapy in small cell lung cancer
شماره ركورد :
14877
Abstract :
Aim: Small cell lung cancer (SCLC) is a progressive and advanced disease. The purpose of this study is to evaluate the response and the hematological side effects of irinotecan chemotherapy in patients with SCLC retrospectively. Materials and Methods: Eighteen patients were included in our study who were between the ages of 30-80 years, had a diagnosis for SCLC, had completed first-line chemotherapy and had taken second-line irinotecan chemotherapy between 01.01.2009 and 01.01.2011. The patients also had archival material which included sufficient information about them and their treatments. All patients had taken at least one course of irinotecan chemotherapy. Data analysis was performed using the SPSS program. Results: Eighteen patients were evaluated. The mean age of the patients was 58.9±7.6 and 89% of the patients were male. After the first-line chemotherapy, treatment response was seen in 78% of the patients and progression was observed in 6% of them. When a radiological evaluation was made after the second-line chemotherapy with irinotecan, a partial response was observed in only 17% of patients, with progression was observed in 61% and stable response was found in 22% of patients. With irinotecan chemotherapy in 28% of patients got improvement of symptoms. The median survival from diagnosis was calculated 91.2±40.2 weeks, the median survival after irinotecan chemotherapy was 31.2±17.2 weeks and time to progression was 15.5±12.0 weeks. Blood transfusion was applicated in 6% of patients and the neutropenia have been observed at least one times in 22% of the patients.Conclusion: It is showed that the second-line irinotecan chemotherapy is partially tolerable although the chemotherapy response rates are low
From Page :
141
NaturalLanguageKeyword :
Small cell lung cancer , irinotecan , survival
JournalTitle :
Ege Journal Of Medicine
To Page :
144
Link To Document :
بازگشت